Oncothermia EHY-2000: Latest technology

Oncological Nanothermia or Oncothermia is a non-invasive modulated electromagnetic hyperthermia method, adjuvant in cancer treatment, which promotes a natural regulatory process of the body.

The Oncotherm® brand was founded in 1988 by Professor Dr. András Szász, as an initiative for the development and research of the electro-hyperthermia method in cancer treatment.

Oncothermia treatment began in Germany 25 years ago, and is currently used in more than 25 countries. It is important to note that in Germany alone equipment has been installed in 4 hospitals and in more than 50 clinics working effectively. In addition, each year more than 100,000 treatments are performed worldwide.

The latest generation model in Oncothermia is: EHY-2000. Currently there are other models of devices, but they do not guarantee the results obtained and investigated by Dr. András Szász.

At the Barcelona Oncothermia Unit you will find the latest technology to offer you the best results.

Scientific publications: Oncothermia journal

Knowledge is a common good that must be shared and placed at the service of society. That is why scientific publications are an important dissemination tool. Paying special attention to treatments as particular as Oncothermia.

Oncological Nanotherapy or Oncothermia is a treatment known and accepted by many oncological specialists and institutions. And of which there are numerous clinical and observational studies in European and international hospitals, with proven and published results. All of them can be consulted in Oncothermia Journal. The articles can be found in electronic or printed version

More information

Also, if you need more information about clinical studies or other publications related to Oncothermia, you can visit the following link, where you will find an extensive list of them.

International Congress of Hyperthermic Oncology

04/15/2016, New Orleans, United States

Hyperthermic Oncothermia is present internationally at congresses and conferences. Thus, in these scientific meetings, doctors give presentations to disseminate the results of clinical cases. Therefore, in this blog, we will inform about the events that take place, such as the following International Congress:

International Congress of Hyperthermic Oncology

Oncothermia is present internationally in congresses and conferences. In these scientific meetings doctors make presentations to disseminate the results of clinical cases. In this blog, we will inform about the events that take place.

On April 15, 2016 in New Orleans, United States, took place the International Congress of Hyperthermic Oncology (12th International Congress of Hyperthermic Oncology). In the United States, Hyperthermia is mainly applied in Oncology as a coadjuvant treatment. In the Congress presented results of the effect of Oncothermia with precise doses of radiotherapy (“Stereotaxis”) with excellent results.

Many interesting posters were presented. It is worthy of mention the presentations of: Dr. Michael Jackson of Canada and Dr. Heui-Kwan Lee of Korea.

  • Dr. Michael Jackson, et.a.:A preliminary in vitro evaluation of oncothermia on a normal and cancerous cell line.
  • Dr. Heui-Kwan Lee, et.al.: Iron-dextran as an ideal thermosensitizer in the radiofrequency-induced hyperthermia

Finally, if you want more information about the events related to Oncothermia treatment, you can visit the following website.

International Lungcancer Symposium

Oncothermia is an adjuvant method for the treatment of cancers, as in the case of Lung Cancer. It stands out for being a non-invasive method that can be combined with radiotherapy and chemotherapy.

Oncothermia is present internationally in congresses and conferences. In these scientific meetings doctors make presentations to disseminate the results of clinical cases.

2nd International Symposium on lung cancer

On April 17, 2016, in Budapest, the 2nd International Symposium on Lung Cancer took place (2nd International Lungcancer Symposium). The conference was organized in different sections. Professor Szasz directed the section: “Oncothermia in Advanced Lung Cancer”, where he presented his latest research and clinical results.

Ensayos clínicos: Oncothermia y Cáncer

Clinical trials: Oncothermia and Cancer.

Oncothermia is an active part of current medical research. There are several Clinical Trials, in patients with cancer, performed in different hospitals around the world.

Clinical trials are a basic tool for the development of drugs and medical devices, in order to improve the current treatment of diseases and develop health tools worldwide.

Clinicaltrials.gov is an internationally recognized web page, where researchers publish the latest clinical trials that are carried out in different hospitals around the world. Oncothermia is present on this website. We will inform you about the latest advances in Oncothermia and Cancer.

Clinical study of Oncothermia applied to a patient with malignant ascites

The clinical study “Oncothermia + intraperitoneal chemotherapy in malignant ascites: Phase II” (Local mEHT * + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT (OTMA-RII) of Prof. Pang, Clifford Hospital, Guangzhou, China) began to include patients in January 2014 and ended in March 2016. The research included two groups of 130 patients. The “experimental group” will be treated with: diet, Chinese herbal medicine and Oncothermia. Instead, the “control group” will be treated with chemotherapy.

We will be attentive to the conclusions of the study!

Clinical trial “Oncothermia + intraperitoneal chemotherapy in malignant ascites: Phase II

Oncothermia: its presence in the world

Oncothermia is a natural adjuvant and non-invasive method to treat cancer. It has now been distributed worldwide. It is present in 24 countries.

These are more than 180 facilities, including public hospitals and private clinics. It should be noted that more than 200,000 treatments are performed annually.

In Germany alone, Oncothermia equipment has been installed in 4 public hospitals, in addition to 80 private clinics. Among them the most relevant are:

  • Uni-Zentrum Naturheilkunde, Institute Universitäts Klinikum, Freiburg
  • Klinikum der LMU – München; Klinikum,Region Hannover
  • Krankenhaus Siloah Medizinische Klinik Hannover
  • Medizinische Versorgungszentren Altenburger
  • Institute of MikrotherapieWithen—Bochum

In Barcelona

The Barcelona Oncothermia Unit is equipped with the latest generation EHZ-2000 model, placing it as a local and global benchmark.

If you need more information, you can consult the different Oncothermia facilities by country.

Oncothermia como patente cáncer

Oncothermia receives the patent as a “tumor vaccine”

This treatment alerts our immune system by checking the cancer cells.

The Oncothermia EHY-2000 plus device received the patent, US 20150217099 A1 in August 2015, describing this treatment as “a tumor vaccine”. It refers to “a vaccine” because it stimulates the immune system and radiofrequency promotes apoptosis or cell death of tumor cells.

Oncothermia is effective for the primary tumor and its metastases. Therefore, it has a local and systemic effect.

Procedure of action of the “vaccine”

The applied technique is called Modulated Electro-Hyperthermia (mEHT). The cancer cells in our body when treated with mEHT produce “heat shock proteins” when they are heated. This treatment alerts our immune system by checking the cancer cells. In this way, these cells are recognized by our immune system and eliminate them.

We all have approximately 1000 cancer cells that circulate in our body every day. Those with a weak immune system can develop a tumor.

In conclusion

For patients diagnosed with cancer, Oncothermia is an excellent option for immunotherapy to complement conventional treatments: surgery, chemotherapy or radiotherapy, in an integrative oncology framework.

You can obtain more information about the operation of Oncothermia for treatments in cancer patients through this link.

Oncothermia versus Hyperthermia: cellular effects in complementary cancer treatments.

Oncothermia is based on the Hyperthermia method, frequently used for cancer treatmentsBut unlike conventional Hyperthermia, Oncothermia, in addition to producing an absolute increase in the temperature of the deep tissue layers, also combines the action of the modulated electric field, with a carrier frequency of 13.56MHz, which is generated by two electrodes assets.

This electric field allows an absorption of energy in the extracellular fluid (ECM), and the imbalance and destructuration of the membrane of the cancer cells achieving important effects at only 38ºC.

Selective capacity of Oncothermia with respect to Hyperthermia

Microbiological studies have shown that cancerous tissues have a greater conductivity in relation to healthy tissues, due to metabolic differences. It is for this reason that the electric field tends to flow preferentially in the malignant tumor tissue, selecting the cells to be treated.

The natural activity of malignant cells is inhibited, dying by apoptosis, that is, by a natural process of cell death induced by the immune system without overloading toxins in the body; unlike necrosis, pathological cell death, produced in conventional hyperthermia.


While conventional hyperthermia disperses heat, oncothermia focuses on the tumor, captures cancer cells by the frequency they emit, focusing it and making it more effective.

If you wish, you can find more information about Oncotermia treatment on our website.

efecto radiosensibilizante en el Cáncer de PulmónOncothermia in combination with Radiotherapy exerts a radiosensitizing effect in lung cancer.

The sensitivity of tumors to radiotherapy and chemotherapy is increased by Oncothermia.

Oncothermia, also known as electro-hyperthermia, is a new treatment modality that allows for increased sensitivity to other treatments. It has been developed to overcome the problems of traditional hyperthermia by targeting malignant tissues.

A study was published in 2015 in the journal Experimental and Therapeutic Medicine. It reports the outcome of combined oncothermia and RT in a 75-year-old patient with stage IIIB non-small-cell lung cancer (NSCLC).

Due to the advanced age and the performance status of the patient, the combination of systemic chemotherapy and RT was deemed infeasible. Therefore, the patient instead decided to undergo oncothermia concurrently with definitive RT.

The RT was administered at a dose of 64.8 Gy in 36 fractions using a three-dimensional conformal plan technique. In this case, Oncothermia was started concomitantly with RT. And was performed for 60 min per session, two sessions per week, for a total of 12 sessions.

Follow-up computed tomography showed complete tumor response. And the patient was alive with no evidence of the disease 18 months after the completion of the treatment.

In conclusion, the present case report suggests that oncothermia combined with RT has former possessing radiosensitizing potential and no additional toxicities. May be it is a promising alternative for advanced-age and/or frail patients with locally advanced NSCLC.

In addition, you can find more information about lung cancer on our website.

Stage IV Kidney Cancer (Wilms Tumor) treated by Oncothermia and herbs

[message_box title=”Wilms tumour is the most common cause of kidney cancer in childhood and adolescence.” color=”red”]It also carries a mortality rate of 7-8 in one million. The 5-year survival rate for kidney cancer is 77.2 – 87.5%. When Wilms tumour progresses, radiotherapy and chemotherapy are conventionally used as the only treatments.[/message_box]

Clinical case

A 17-year-old Korean woman was treated from October 25, 2014, until July 22, 2015 with an integrating medical treatment, in order to control the extent of her illness.

The integrative medical treatment included: oncothermia, thymosin-α1 and phytotherapy. Phytotherapy was administered in 8 ml. of inhalation of Soram nebulizer solution qd, Soramdan S 8 g po, Hangamdan S 1 g po, tid, Cheongjangtang 10-30 ml, and Spiam HC 8 g po. She received Oncothermia (2-3 times a week) and 1.6 mg of treatment with thymosin-α1 (Zadaxin) i.m.


According to the result of the CT on July 15, 2015, the liver metastasis was no longer seen, while the lung metastasis remained stable without tumor progression.


In patterns of Wilms tumor progression after surgery and chemotherapy, integrative medical treatment can be significant for disease control.


Lee D, Kim SS, Seong S, Cho W, Yu H. Stage IV Wilms Tumor Treated by Korean Medicine, Hyperthermia and Thymosin-α1: A Case Report. Case Rep Oncol. 2016 Feb 20;9(1):119-25. doi: 10.1159/000443724. 

If you wish, you can find more information about clinical cases treated with Oncotermia on our website.